Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(1):98–103. doi: 10.1111/j.1349-7006.2004.tb03177.x

Intratumoral injection of IL‐2‐activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde‐fixed tumor vaccine in a rat intracranial brain tumor model

Eiichi Ishikawa 1,2, Koji Tsuboi 1, Shingo Takano 1, Eiji Uchimura 2, Tadao Nose 1, Tadao Ohno 2,3,✉
PMCID: PMC11158400  PMID: 14720334

Abstract

Combined therapy with a fixed‐tumor cell vaccine and intratumoral injection of NK cells induced strong tumor regression of rat glioma. Rat 9L glioma cells were inoculated into syngeneic male rats at the flank (subcutaneous tumor model) or at the basal ganglia of the right hemisphere (intracranial tumor model). Rats were intradermally injected three times with vaccine comprising fixed 9L cells, IL‐2‐ and GMCSF‐microparticles, and tuberculin prior to (protective studies) or after (therapeutic studies) challenge with live 9L cells. In the protective studies, the vaccine alone achieved significant tumor growth inhibition and elongation of mean life span in both the subcutaneous and intracranial tumor models. No therapeutic effect was observed in the intracranial tumor model with the vaccine alone. However, intratumoral injection of rat NK cells strongly assisted the therapeutic effect of the vaccine in the brain tumor model and resulted in a statistically significant elongation of life span. We propose that intratumoral injection of NK cells may not only kill brain tumor cells directly, but also trigger a strong immune response in the focal lesion of the brain after vaccination. (Cancer Sci 2004; 95: 98–103)

References

  • 1. Committee of Brain Tumor Registry of Japan [No authors listed] Report of Brain Tumor Registry of Japan (1969–1993). Neurol Med Chir (Tokyo) 2000; 40 Suppl: 1–106. [PubMed] [Google Scholar]
  • 2. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 6: 259–73. [DOI] [PubMed] [Google Scholar]
  • 3. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin‐2 therapy of human gliomas. J Neuro surg 1989; 70: 175–82. [DOI] [PubMed] [Google Scholar]
  • 4. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76: 840–52. [DOI] [PubMed] [Google Scholar]
  • 5. Nakagawa K, Kamezaki T, Shibata Y, Tsunoda T, Meguro K, Nose T. Effect of lymphokine‐activated killer cells with or without radiation therapy against malignant brain tumors. Neurol Med Chir (Tokyo) 1995; 35: 22–7. [DOI] [PubMed] [Google Scholar]
  • 6. Tsuboi K, Saijo K, Ishikawa E, Tsurushima H, Takano S, Morishita Y, Ohno T. Effects of local injection of ex vivo expanded autologous tumor specific T‐ lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003; 15: 3294–302. [PubMed] [Google Scholar]
  • 7. Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, Saijo K, Ohno T. Reduction of end‐stage malignant glioma by injection with autolo‐gous cytotoxic T lymphocytes. Jpn J Cancer Res 1999; 90: 536–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT. Observations on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin‐2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92. [DOI] [PubMed] [Google Scholar]
  • 9. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high‐dose interleukin‐2 alone. N Engl J Med 1987; 316: 889–97. [DOI] [PubMed] [Google Scholar]
  • 10. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA. Prospective randomized trial of high‐dose interleukin‐2 alone or in conjunction with lymphokine‐activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622–32. [DOI] [PubMed] [Google Scholar]
  • 11. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive im‐munotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802–7. [DOI] [PubMed] [Google Scholar]
  • 12. Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell‐mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572–7. [PubMed] [Google Scholar]
  • 13. Livingston PO, Albino AP, Chung TJ, Real FX, Houghton AN, Oettgen HF, Old LJ. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 1985; 55: 713–20. [DOI] [PubMed] [Google Scholar]
  • 14. Powles RL, Russell JA, Selby PJ, Prentice HG, Jones DR, McElwain TJ, Alexander P. Maintenance of remission in acute myelogenous leukemia by a mixture of B.C.G. and irradiated leukemia cells. Lancet 1977; 2: 1107–10. [DOI] [PubMed] [Google Scholar]
  • 15. Soiffer R, Lynch T, Mihm M, Jung K, Rhudo C, Schmollinger JC, Hodi ES, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Soher A, Bhan A, Daley J, Veabery D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Coben LK, Mulligan RC, Dranoff G. Vaccine with irradiated autologous melanoma cells engineered to secrete human granulocyte‐macrophage colony‐stimulating factor generates potent antitu‐mor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow‐derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90: 1115–24. [DOI] [PubMed] [Google Scholar]
  • 17. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor lysate‐pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513–9. [PubMed] [Google Scholar]
  • 18. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. Vaccination of malignant glioma patients with peptide–pulsed dendritic cells elicits systemic cytotoxicity and intracranial T‐cell infiltration. Cancer Res 2001; 61: 842–7. [PubMed] [Google Scholar]
  • 19. Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA‐A 2402‐restricted and carcinoembryonic‐antigen‐specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47: 90–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Kim CH, Todoroki T, Matsumura M, Ohno T. Eligibility of antigenic‐pep‐tide‐pre‐loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen. J Cancer Res Clin Oncol 2000; 126: 383–90. [DOI] [PubMed] [Google Scholar]
  • 21. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin‐fixed and paraffin‐embedded tumour sections. Nat Med 1995; 1: 267–71. [DOI] [PubMed] [Google Scholar]
  • 22. Liu SQ, Shiraiwa H, Kawai K, Hayashi H, Akaza H, Kim BS, Oki A, Nishida M, Kubo T, Hashizaki K, Saijo K, Ohno T. Tumor–specific autologous cytotoxic T lymphocytes from tissue section. Nat Med 1996; 2: 1283. [DOI] [PubMed] [Google Scholar]
  • 23. Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L, Huang J, Lu MD, Liang LJ, Leong KW, Ohno T. Autologous fixed tumor vaccine: a formulation with cytokine‐microparticles for protective immunity against recurrence of human hepatocellular carcinoma. J pn J Cancer Res 2002; 93: 363–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Aarli JA. The immune system and the nervous system. J Neurol 1983; 229: 137–54. [DOI] [PubMed] [Google Scholar]
  • 25. Chambers WH, Bozik ME, Brissette‐Storkus SC, Basse P, Redgate E, Watkins S, Boggs SS. NKR‐P1+ cells localize selectively in Rat 9L gliosar‐comas but have reduced cytolytic function. Cancer Res 1996; 56: 3516–25. [PubMed] [Google Scholar]
  • 26. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R. RG‐2 glioma growth attenuation and severe brain edema caused by local production of interleukin–2 and interferon–gamma. Cancer Res 1995; 55: 1902–10. [PubMed] [Google Scholar]
  • 27. Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K. Intratumoral cy‐togenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 1998; 58: 4694–700. [PubMed] [Google Scholar]
  • 28. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area‐specific CGH on microdissected tumor cells. J Neuro-pathol Exp Neurol 1999; 58: 993–9. [DOI] [PubMed] [Google Scholar]
  • 29. Graf MR, Prins RM, Hawkins WT, Merchant RE. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol Immunother 2002; 51: 179–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Lumniczky K, Desaknai S, Mangel L, Szende B, Hamada H, Hidvegi EJ, Safrany G. Local tumor irradiation augments the antitumor effect of cytok‐ine‐producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002; 9: 44–52. [DOI] [PubMed] [Google Scholar]
  • 31. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221–44. [DOI] [PubMed] [Google Scholar]
  • 32. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92: 441–50. [DOI] [PubMed] [Google Scholar]
  • 33. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte‐macrophage colony‐stimulating factor in patients with metastatic melanoma. J Immunother 2000; 23: 275–81. [DOI] [PubMed] [Google Scholar]
  • 34. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160–6. [DOI] [PubMed] [Google Scholar]
  • 35. Iwadate Y, Namba H, Sakiyama S, Yamaura A, Tagawa M. Interleukin‐12‐mediated induction of systemic immunity in the periphery and recruitment of activated T cells into the brain produce limited antitumor effects compared with interleukin‐2. Int J Mol Med 2002; 10: 741–7. [PubMed] [Google Scholar]
  • 36. Iwadate Y, Yamaura A, Sato Y, Sakiyama S, Tagawa M. Induction of immunity in peripheral tissues combined with intracerebral transplantation of in‐terleukin‐2‐producing cells eliminates established brain tumors. Cancer Res 2001; 61: 8769–74. [PubMed] [Google Scholar]
  • 37. Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, Thomas EK, Nickoloff BJ, Mule JJ. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis‐in‐ducing agents. Cancer Res 2001; 61: 228–36. [PubMed] [Google Scholar]
  • 38. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti‐tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002; 51: 424–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, Inoue H, Mori M. Intratumoral injection of dendritic cells after treatment of anti‐cancer drugs induces tumor‐specific antitumor effect in vivo. Int J Cancer 2002; 101: 265–9. [DOI] [PubMed] [Google Scholar]
  • 40. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell‐deficient mice. Proc Natl Acad Sci USA 2000; 97: 2731–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Gerosa F, Baldani‐Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact‐dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 335–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Allavena P, Bianchi G, Paganin C, Giardina G, Mantovani A. Regulation of adhesion and transendotherial migration of natural killer cells. Nat Immun 19967; 15: 107–16. [PubMed] [Google Scholar]
  • 44. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N, Umehara H. Fractalkine–mediated endothelial cell injury by NK cells. J Immunol 2000; 164: 4055–62. [DOI] [PubMed] [Google Scholar]
  • 45. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995; 378: 245–8. [DOI] [PubMed] [Google Scholar]
  • 46. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti‐p58 antibodies reconstitute lysis of MHC class I‐pro‐tected cells in NK clones displaying different specificities. J Exp Med 1993; 178: 597–604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I, Ohno T. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 2002; 93: 313–9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES